Neuropeptides and other chemical mediators, and the role of antiinflammatory drugs in primary headaches

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2010, Pages 170-188

  Samsam, Mohtashem ^a,c   Covenas, Rafael ^b   Ahangari, Raheleh ^a   Yajeya, Javier ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c International University of Health Sciences (IUHS)   (Australia)

Author keywords

Anti inflammatory drugs; Headache; Neuropeptide

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CODEINE SULFATE; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE TARTRATE; FLURBIPROFEN; MECLOFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NARATRIPTAN; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OLCEGEPANT; OPIATE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIZATRIPTAN; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SEROTONIN AGONIST; SOMATOSTATIN; SUMATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CLINICAL TRIAL; CLUSTER HEADACHE; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; DEPRESSION; DIFFICULTY SWALLOWING; DIGESTIVE SYSTEM DISEASE; DIZZINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; FATIGUE; HUMAN; MEDIATOR RELEASE; MIGRAINE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; NOSE CONGESTION; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL VASCULAR DISEASE; PRIMARY HEADACHE; SENSITIZATION; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SIDE EFFECT; TENSION HEADACHE; THORAX PAIN; THROAT TIGHTNESS; TINGLING SENSATION; TRIGEMINAL NERVE; TRIGEMINUS GANGLION; VOMITING;

EID: 77958452903     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871523011009030170     Document Type: Article

References (261)

1. Olesen, J.; Bonica, J.J. In: The Management of Pain; Bonica, J.J. Ed.; Lea & Febiger: Philadelphia, 1990, Vol. 1, pp. 687-726.
2. Goadsby, P.J. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol. Med., 2007, 13, 39-44.
3. Goadsby P.J. The vascular theory of migraine--a great story wrecked by the facts. Brain, 2009, 132, 6-7.
4. Olsen, J. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia, 2004, 241, 9-160.
5. Stovner, L.J.; Andrée, C. Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J. Headache Pain, 2008, 9, 139-146.
6. Lipton, R.B.; Stewart, W.F.; Diamond, S.; Diamond, M.L.; Reed, M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 2001, 41, 646-657.
7. Rasmussen, B.K.; Olesen, J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia, 1992, 12, 221-228.
8. Gérardy, P.Y.; Fumal, A.; Schoenen, J. Epidemiology and economic repercussion of headache: an inquiery among the administrative and technical personnel of the Liège University. Rev. Med. Liege, 2008, 63, 310-314.
9. Breslau, N.; Rasmussen, B.K. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology, 2001, 56, S4-12.
10. Blau, J.N. Migraine prodromes separated from the aura: complete migraine. Br. Med. J., 1980, 281, 658-660.
11. Linde, M. Migraine: a review and future directions for treatment. Acta Neurol. Scand., 2006, 114, 71-83.
12. Schoonman, G.G.; Evers, D.J.; Terwindt, G.M.; van Dijk, J.G.; Ferrari, M.D. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia, 2006, 26, 1209-13.
13. Whyte, C.A.; Tepper, S.J. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev. Neurother., 2009, 9, 1379-1391.
14. Evers, S.; Afra, J.; Frese, A.; Goadsby, P.J.; Linde, M.; May, A.; Sándor, P.S. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur. J. Neurol., 2006, 13, 560-572.
15. Moskowitz, M.A. The neurobiology of vascular head pain. Ann. Neurol., 1984, 16, 157-168.
16. Lance, J.W.; Lambert, G.A.; Goadsby, P.J.; Duckworth, J.W. Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache, 1983, 23, 258-265.
17. Goadsby, P.J.; Zagami, A.S.; Lambert, G.A. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache, 1991, 31, 365-371.
18. Goadsby, P.J. Migraine aura: a knockin mouse with a knockout message. Neuron, 2004, 41, 679-780.
19. Goadsby, P.J.; Kullmann, D.M. Another migraine gene. Lancet, 2005, 366, 345-346.
20. Ophoff, R.A.; Terwindt, G.M.; Vergouwe, M.N.; van Eijk, R.; Oefner, P.J.; Hoffman, S.M.; Lamerdin, J.E.; Mohrenweiser, H.W.; Bulman, D.E.; Ferrari, M.; Haan, J.; Lindhout, D.; van Ommen, G.J.; Hofker, M.H.; Ferrari, M.D.; Frants, R.R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell, 1996, 87, 543-552.
21. Ophoff, R.A.; Van den Maagdenberg, A.M.; Roon, K.I.; Ferrari, M.D.; Frants, R.R. The impact of pharmacogenetics for migraine. Eur. J. Pharmacol., 2001, 413, 1-10.
22. De Fusco, M.; Marconi, R.; Silvestri, L.; Atorino, L.; Rampoldi, L.; Morgante, L.; Ballabio, A.; Aridon, P.; Casari, G. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet., 2003, 33, 192-196.
23. Vanmolkot, K.R.; Kors, E.E.; Hottenga, J.J.; Terwindt, G.M.; Haan, J.; Hoefnagels, W.A.; Black, D.F.; Sandkuijl, L.A.; Frants, R.R.; Ferrari, M.D.; van den Maagdenberg, A.M. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann. Neurol., 2003, 54, 360-366.
24. Dichgans, M.; Freilinger, T.; Eckstein, G.; Babini, E.; Lorenz-Depiereux, B.; Biskup, S.; Ferrari, M.D.; Herzog, J.; van den Maagdenberg, A.M.; Pusch, M.; Strom, T.M. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet, 2005, 366, 371-377.
25. Goadsby, P.J.; Lipton, R.B.; Ferrari, M.D. Migraine--current understanding and treatment. N. Engl. J. Med., 2002, 346, 257-270.
26. Kors, E.E.; Vanmolkot, K.R.; Haan, J.; Frants, R.R.; van den Maagdenberg, A.M.; Ferrari, M.D. Recent findings in headache genetics. Curr. Opin. Neurol., 2004, 17, 283-288.
27. Wessman, M.; Kaunisto, M.A.; Kallela, M.; Palotie, A. The molecular genetics of migraine. Ann. Med., 2004, 36, 462-473.
28. van den Maagdenberg, A.M.; Pietrobon, D.; Pizzorusso, T.; Kaja, S.; Broos, L.A.; Cesetti, T.; van de Ven, R.C.; Tottene, A.; van der Kaa, J.; Plomp, J.J.; Frants, R.R.; Ferrari, M.D. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron, 2004, 41, 701-710.
29. Lauritzen, M.; Olsen, T.; Lassen, N.; Paulson, O. Regulation of regional cerebral blood flow during and between migraine attacks. Ann. Neurol., 1983, 14, 569-572.
30. Lauritzen, M. Cortical spreading depression in migraine. Cephalalgia, 2001, 21, 757-760.
31. Gorji, A. Spreading depression: a review of the clinical relevance. Brain Res. Brain Res. Rev., 2001, 38, 33-60.
32. Sánchez-del-Rio, M.; Reuter, U. Migraine aura: new information on underlying mechanisms. Curr. Opin. Neurol., 2004, 17, 289-293.
33. Tfelt-Hansen, P.; Ashina, M.; Olesen, J. Clinical symptoms and pathophysiology of migraine. Ugeskr. Laeger., 2008, 170, 3231-3234.
34. Spierings, ELH. The aura-headache connection in migraine: a historical analysis. Arch. Neurol., 2004, 61, 794-799.
35. Wolthausen, J.; Sternberg, S.; Gerloff, C.; May, A. Are cortical spreading depression and headache in migraine causally linked? Cephalalgia, 2009, 29, 244-9.
36. Hauge, A.W.; Asghar, M.S.; Schytz, H.W.; Christensen, K.; Olesen, J. Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study. Lancet Neurol., 2009, 8, 718-23.
37. Weiller, C.; May, A.; Limmroth, V.; Juptner, M.; Kaube, H.; Schayck, R.V.; Coenen, H.H.; Diener, H.C. Brain stem activation in spontaneous human migraine attacks. Nat. Med., 1995, 1, 658-660.
38. Spierings, E.L.H. Pathogenesis of the migraine attack. Clin. J. Pain, 2003, 19, 255-262.
39. Denuelle, M.; Fabre, N.; Payoux, P.; Chollet, F.; Geraud, G. Hypothalamic activation in spontaneous migraine attacks. Headache, 2007, 47, 1418-1426.
40. Bahra, A.; Matharu, M.S.; Buchel, C.; Frackowiak, R.S.; Goadsby, P.J. Brainstem activation specific to migraine headache. Lancet, 2001, 357, 1016-1017.
41. Matharu, M.S.; Bartsch, T.; Ward, N.; Frackwiak, R.S.; Weiner, R.; Goadsby, P.J. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain, 2004, 127, 220-230.
42. Géraud, G.; Denuelle, M.; Fabre, N.; Payoux, P.; Chollet, F. Positron emission tomographic studies of migraine. Rev. Neurol. Paris, 2005, 161, 666-670.
43. Afridi, S.K.; Giffin, N.J.; Kaube, H.; Friston, K.J.; Ward, N.S.; Frackowiak, R.S.; Goadsby, P.J. A positron emission tomographic study in spontaneous migraine. Arch. Neurol., 2005, 62, 1270-1275.
44. Cohen, A.S.; Goadsby, P.J. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother., 2006, 6, 1159-1171.
45. Knight, Y.E.; Goadsby, P.J. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience, 2001, 106, 793-800.
46. Knight, Y.E.; Classey, J.D.; Lasalandra, M.P.; Akerman, S.; Kowacs, F.; Hoskin, K.L.; Goadsby, P.J. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res., 2005, 1045, 1-11.
47. Welch, K.M., Nagesh, V.; Aurora, S.K.; Gelman, N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache, 2001, 41, 629-637.
48. Knight, Y.E.; Bartsch, T.; Kaube, H.; Goadsby, P.J. P/Q-type calcium- channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci., 2002, 22, RC213.
49. Burstein, R.; Yarnitsky, D.; Goor-Aryeh, I.; Ransil, B.J.; Bajwa, Z.H. An association between migraine and cutaneous allodynia. Ann. Neurol., 2000, 47, 614-624.
50. Villalón, C.M.; Centurión, D.; Valdivia, L.F.; de Vries, P.; Saxena, P.R. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West Pharmacol. Soc., 2002, 45, 199-210.
51. Silberstein, S.D. Migraine pathophysiology and its clinical implications. Cephalalgia, 2004, 2, 2-7.
52. Kruuse, C.; Thomsen, L.; Birk, S.; Oleesen, J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003, 126, 241-247.
53. Jensen, R.; Olesen, J. Tension-type headache: an update on mechanisms and treatment. Curr. Opin. Neurol., 2000, 13, 285-289.
54. Lindsay, K.W.; Bone, I. Neurology and Neurosugery Illustrated, 4th ed.; Churchill Livingstone: Philadelphia, 2004.
55. Mørk, H.; Ashina, M.; Bendtsen, L.; Olesen, J.; Jensen, R. Induction of prolonged tenderness in patients with tension-type headache by means of a new experimental model of myofascial pain. Eur. J. Neurol., 2003, 10, 249-256.
56. Bendtsen, L. Central sensitization in tension-type headache-- possible pathophysiological mechanisms. Cephalalgia, 2000, 20, 486-508.
57. Ashina, S.; Bendtsen, L.; Ashina, M.; Magerl, W.; Jensen, R. Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia, 2006, 26, 940-948.
58. Fernández-de-las-Peñas, C.; Cuadrado, M.L.; Arendt-Nielsen, L.; Simona, D.G.; Pareja, J.A. Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia, 2007, 27, 383-393.
59. Bach, F.W.; Langemark, M.; Ekman, R.; Rehfeld, J.F.; Schifter, S.; Olesen, J. Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. Neuropeptides, 1994, 27, 129-136.
60. Ashina, M.; Bendtsen, L.; Jensen, R.; Ekman, R.; Olesen, J. Plasma levels of substance P, neuropeptide Y and vasoactive intestinal polypeptide in patients with chronic tension-type headache. Pain, 1999, 83, 541-547.
61. Ashina, M.; Bendtsen, L.; Jensen, R.; Schifter, S.; Jansen-Olesen, I.; Olesen, J. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology, 2000, 55, 1335-1340.
62. Ashina, M.; Bendtsen, L.; Jensen, R.; Sakai, F.; Olesen, J. Possible mechanisms of glyceryl-trinitrate-induced immediate headache in patients with chronic tension-type headache. Cephalalgia, 2000, 20, 919-924.
63. Goadsby, P.J.; Edvinsson, L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain, 1994, 117, 427-434.
64. Goadsby, P.J.; Lipton, R.B. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain, 1997, 120, 193-209.
65. May, A.; Goadsby, P.J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cereb. Blood Flow Metab., 1999, 19, 115-127.
66. May, A.; Ashburner, J.; Büchel, C.; McGonigle, D.J.; Friston, K.J; Frackowiak, R.S.; Goadsby, PJ. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat. Med., 1999, 5, 836-838.
67. May, A.; Bahra, A.; Büchel, C.; Frackowiak, R.S.; Goadsby, P.J. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology, 2000, 55, 1328-1335.
68. Matharu, M.S.; Cohen, A.S.; Frackowiak, R.S.; Goadsby, P.J. Posterior hypothalamic activation in paroxysmal hemicrania. Ann. Neurol., 2006, 59, 535-545.
69. Sprenger, T.; Valet, M.; Platzer, S.; Pfaffenrath, V.; Steude, U.; Tolle, T.R. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain, 2005, 113, 422-426.
70. Goadsby, P.J.; Edvinsson, L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain, 1994, 117, 427-434.
71. Fanciullacci, M.; Alessandri, M.; Figini, M.; Geppetti, P.; Michelacci, S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain, 1995, 60, 119-123.
72. Zagami, A.S.; Goadsby, P.J.; Edvinsson, L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides, 1990, 16, 69-75.
73. Edvinsson, L. Sensory nerves in man and their role in primary headaches. Cephalalgia, 2001, 21, 761-764.
74. Edvinsson, L.; Uddman, R. Neurobiology of primary headaches. Brain Res. Rev., 2005, 48, 438-456.
75. Edvinsson, L. Neuronal signal substances as biomarkers of migraine. Headache, 2006, 46, 1088-1094.
76. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya J. In: Neuroanatomy Research Advances; Flynn, C. E.; Callaghan, B.R. Ed.; Nova Science Publishers: New York; 2009, pp.1-58.
77. McBean, D.E.; Sharkey, J.; Ritchie, I.M.; Kelly, P.A. Evidence for a possible role for serotonergic systems in the control of cerebral blood flow. Brain Res., 1990, 537, 307-310.
78. Edvinsson, L.; Degueurce, A.; Duverger, D.; MacKenzie, E.T.; Scatton, B. Central serotonergic nerves project to the pial vessels of the brain. Nature, 1983, 306, 55-57.
79. Sakai, Y.; Dobson, C.; Diksic, M.; Aubé, M.; Hamel, E. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology, 2008, 70, 431-439.
80. Hamel, E. Serotonin and migraine: biology and clinical implications. Cephalalgia, 2007, 27, 1293-300.
81. Panconesi, A. Serotonin and migraine: a reconsideration of the central theory. J. Headache Pain., 2008, 9, 267-276.
82. Zhang, X.; Strassman, A.M.; Burstein, R.; Levy, D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther., 2007, 322, 806-812.
83. Humphrey, P.P.; Feniuk, W.; Marriott, A.S.; Tanner, R.J.; Jackson, M.R.; Tucker, M.L. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol., 1991, 31, 282-290.
84. Ramadan, N.M.; Skljarevski, V.; Phebus, L.A.; Johnson, K.W. 5- HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia., 2003, 23, 776-785.
85. Villalón, C.M.; Olesen, J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther., 2009, 124, 309-323.
86. Humphrey, P.P. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008, 48, 685-687.
87. Bigal, M.E.; Krymchantowski, A.V.; Ho, T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq. Neuropsiquiatr., 2009, 67, 559-569.
88. Houghton, L.A.; Fowler, P.; Keene, O.N.; Read, N.W. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment. Pharmacol. Ther., 1992, 6, 685-691.
89. Cipolla, G.; Sacco, S.; Crema, F.; Moro, E.; De Ponti, F.; Frigo, G. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol. Res., 2001, 43, 205-210.
90. Longmore, J.; Razzaque, Z.; Shaw, D.; Davenport, A.P.; Maguire, J.; Pickard, J.D.; Schofield, W.N.; Hill, R.G. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br. J. Clin. Pharmacol., 1998, 46, 577-582.
91. van den Broek, R.W.; MaassenVanDenBrink, A.; de Vries, R.; Bogers, A.J.; Stegmann, A.P.; Avezaat, C.J.; Saxena, P.R. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur. J. pharmacol., 2000, 407, 165-173.
92. MaassenVanDenBrink, A.; van den Broek, R.W.; de Vries, R.; Bogers, A.J.; Avezaat, C.J.; Saxena, P.R. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology, 2000, 55, 1524-1530
93. Bou, J.; Gras, J.; Cortijo, J.; Morcillo, E.J.; Llenas, J.; Palacios, J.M. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia, 2001, 21, 804-812.
94. Maassen Van Den Brink, A.; Saxena, P.R. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache, 2004, 44(Suppl 1): S13-19.
95. Bigal, M.E.; Lipton, R.B. Excessive acute migraine medication use and migraine progression. Neurology., 2008, 71, 1821-8.
96. Silberstein, S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000, 55, 754-62.
97. Demaagd, G. The pharmacological management of migraine, part 1: overview and abortive therapy. Pharm. Ther., 2008, 33, 404-16.
98. DeMaagd, G. The pharmacological management of migraine, part 2: preventative therapy. Pharm. Ther., 2008, 33, 480-487.
99. Panconesi, A.; Anselmi, B.; Curradi, C.; Perfetto, F.; Piluso, A.; Franchi, G. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache, 1994, 34, 194-7.
100. Saper, J.R.; Silberstein, S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache, 2006, 46, Suppl 4:S171-81.
101. Tfelt-Hansen, P. Ergotamine, dihydroergotamine: current uses and problems. Curr Med. Res. Opin., 2001, 17(Suppl 1), s30-34.
102. Tfelt-Hansen, P. Triptans versus other migraine medicine-- secondary publication, Ugeskr. Laeger., 2009, 171, 1485-7.
103. Arulmani, U.; Gupta, S.; Massen Van Den Brink, A.; Centurion, D.; Villalon, C.M.; Saxena, P.R. Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 2006, 26, 642-659.
104. Markowitz, S.; Saito, K.; Moskowitz, M.A. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci., 1987, 7, 4129-4136.
105. Knyihár-Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Vécsei, L. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci. Lett., 1995, 184, 189-192.
106. Messlinger, K.; Hanesch, U.; Kurosawa, M.; Pawlak, M.; Schmidt, R.F. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can. J. Physiol. Pharmacol., 1995, 73, 1020-1024.
107. Williamson, D.J., Hargreaves, R.J., Hill, R.G., Shepheard, S.L. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia. 1997, 17, 518-524.
108. Wei, E.P.; Moskowitz, M.A.; Boccalini, P.; Kontos, H.A. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside- induced vasodilation in feline cerebral arterioles. Circ. Res., 1992, 70, 1313-1319.
109. Buzzi, M.G.; Carter, W.B.; Shimizu, T.; Heath III, H.; Moskowitz, M.A. Dihydroergotamine and Sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacol., 1991, 30, 1193-1200.
110. Goadsby, P.J.; Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol., 1993, 33, 48-56.
111. Knyihár Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Buzás, P.; Vécsei, L. Effect of a serotonin agonist (Sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J. Neurosci. Res., 1997, 48, 449-464.
112. Ottosson, A.; Edvinsson, L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia, 1997, 17, 166-174.
113. Schwenger, N.; Dux, M.; de Col, R.; Carr, R.; Messlinger, K. Interaction of calcitonin gene-related peptide, nitric oxide and histamine release in neurogenic blood flow and afferent activation in the rat cranial dura mater. Cephalalgia, 2007, 27, 481-491.
114. Nichols, FI.; Mawad, M.; Mohr, J.; Stein, B.; Hilal, S.; Michelsen, J. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke, 1990. 21, 555-559.
115. Olesen, J.; Friberg, L.; Olesen, T.; Iversen, H.K.; Lassen, N.A.; Andersen, A.R.; Karle, A. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol., 1990, 28, 791-798.
116. May, A.; Buchel, C.; Turner, R.; Goadsby, P.J. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J. Cereb. Blood Flow Metab., 2001, 21, 1171-1176.
117. Knyihár Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Buzás, P.; Vécsei, L. Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion. Exp. Brain Res., 1998, 118, 111-114.
118. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narvaéz, J.A.; Tramu, G. Alterations in neurokinin A, substance P and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion. Neurosci. Let., 1999, 261, 179-182.
119. Samsam, M.; Knyihár-Csillik, E.; Sáry, G.; Vécsei, L. Effects of lesions of the Gasserian ganglion on the CGRP immunoreactivity of the caudal trigeminal nucleus. Neurobiology, 1996, 4, 169.
120. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narvaéz, J.A.; Tramu, G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain, 2000, 84, 389-395.
121. Samsam, M.; Coveñas, R.; Csillik, B.; Ahangari, R.; Yajeya, J.; Riquelme, R.; Narvaéz, J.A.; Tramu, G. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion: a possible neurophysiological and neuroanatomical link to generalized head pain. J. Chem. Neuroanat., 2001, 21, 161-169.
122. Wiesenfeld-Halin, Z.; Hökfelt, T.; Lundberg, J.M.; Forssmann, W.G.; Reinecke, M.; Tschopp, F.A.; Fischer, J.A. Immunoreactive calcitonin gene-related peptide and substance P co-exist in sensory neurons to the spinal cord and interact in spinal behavioural responses of the rat. Neurosci. Lett., 1984, 52, 199-204.
123. Goodman, E.C.; Iversen, L.L. Calcitonin gene-related peptide: Novel neuropeptide. Life Sci., 1986, 38, 2169-2178.
124. Le Greves, P.; Nyberg, F.; Terenius, L.; Hökfelt, T. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur. J. Pharmacol., 1985, 115, 309-311.
125. Le Grevès, P.; Nyberg, F.; Hökfelt, T.; Terenius, L. Calcitonin gene-related peptide is metabolized by an endopeptidase hydrolyzing substance P. Regul. Pept., 1989, 25, 277-286.
126. Oku, R.; Satoh, M.; Fujii, N.; Otaka, A.; Yajima, H.; Takagi, H. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res., 1987, 403, 350-354.
127. Basbaum, A. I.; Woolf, C.J. Pain. Curr. Biol., 1999, 9, R429-R431.
128. Yaksh, T.L. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol. Sci., 1999, 20, 329-337.
129. Ramadan, N.M. The link between glutamate and migraine. CNS Spectr., 2003, 8, 446-449.
130. Mitsikostas, D.D.; Sanchez del Rio, M.; Waeber, C.; Moskowitz, M.A.; Cutrer, F.M. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain, 1998, 76, 239-248.
131. Tfelt-Hansen, P.; Le, H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J. Headache Pain., 2009, 10, 137-43.
132. Olesen, J.; Diener, H.C.; Husstedt, I.W. Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L.M. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med., 2004, 350, 1104-1110.
133. Miller, P.S.; Barwell, J.; Poyner, D.R.; Wigglesworth, M.J.; Garland, S.L.; Donnelly, D. Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem. Biophys. Res. Commun., 2010, 391, 437-42.
134. Zhang, Z.; Winborn, C.S.; Marquez de Prado, B.; Russo, A.F. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci., 2007, 27, 2693-2703.
135. McLatchie, L.M.; Fraser, N.J.; Main, M.J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M.G.; Foord, S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 1998, 393, 333-9.
136. Hay, D.L.; Howitt, S.G.; Conner, A.C.; Doods, H.; Schindler, M.; Poyner, D.R. A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br. J. Pharmacol., 2002, 137, 80-86.
137. Dennis, T.; Fournier, A.; Cadieux, A.; Pomerleau, F.; Jolicoeur, F.B.; St Pierre, S.; Quirion, R. hCGRP8-37, a calcitonin generelated peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther., 1990, 254, 123-128.
138. Hay, D.L.; Poyner, D.R.; Quirion, R. International Union of Pharmacology. Collaborators (5) Born, W.; Fischer, J.; Sexton, P.; Minamino, N.; Kangawa, K. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol. Rev., 2008, 60, 143-145.
139. Kitazono, T.; Heistad, D.D.; Faraci, F.M. Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol., 1993, 265, H581-H585.
140. Hong, K.W.; Yoo, S.E.; Yu, S.S.; Lee, J.Y.; Rhim, B.Y. Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am. J. Physiol., 1996, 270, H317-H323.
141. Parsons, A.M.; Seybold, V.S. Calcitonin gene-related peptide induces the formation of second messengers in primary cultures of neonatal rat spinal cord. Synapse., 1997, 26, 235-242.
142. Birk, S.; Kruuse, C.; Petersen, K.A.; Tfelt-Hansen, P.; Olesen, J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia., 2006, 26, 1304-1309.
143. Bellamy, J.; Bowen, E.J.; Russo, A.F.; Durham, P.L. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci., 2006, 23, 2057-2066.
144. Edvinsson, L.; Alm, R.; Shaw, D.; Rutledge, R.Z.; Koblan, K.S.; Longmore, J.; Kane, S.A. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol., 2002, 434, 49-53.
145. Jansen-Olesen, I.; Jorgensen, L.; Engel, U.; Edvinsson, L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur. J. Pharmacol., 2003, 481, 207-216.
146. Wu, D.; Eberlein, W.; Rudolf, K.; Engel, W.; Hallermayer, G.; Doods, H. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur. J. Pharmacol., 2000, 400, 313-319.
147. Jansen-Olesen, I.; Kaarill, L.; Edvinsson, L. Characterization of CGRP(1) receptors in the guinea pig basilar artery. Eur. J. Pharmacol., 2001, 414, 249-258.
148. Wu, D.; Doods, H.; Arndt, K.; Schindler, M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem. Soc. Trans., 2002, 30, 468-473.
149. Gupta, S.; Akerman, S.; van den Maagdenberg, A.M.; Saxena, P.R.; Goadsby, P.J.; van den Brink, A.M. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia, 2006, 26, 1294-1303.
150. Petersen, K.A.; Birk, S.; Lassen, L.H.; Kruuse, C.; Jonassen, O.; Lesko, L.; Olesen, J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia, 2005, 25, 139-147.
151. Tröltzsch, M.; Denekas, T.; Messlinger, K. The calcitonin generelated peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur. J. Pharmacol., 2007, 562, 103-110.
152. Gupta, S.; Mehrotra, S.; Villalon, C.M.; Garrelds, I.M.; de Vries, R.; van Kats, J.P.; Sharma, H.S.; Saxena, P.R.; Maassen van den brink, A. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur. J. Pharmacol., 2006, 530, 107-116.
153. Hasbak, P.; Saetrum Opgaard, O.; Eskesen, K.; Schifter, S.; Arendrup, H.; Longmore, J.; Edvinsson, L. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J. Pharmacol. Exp. Ther., 2003, 304, 326-333.
154. Ho, TW.; Mannix, L.K.; Fan, X.; Assaid, C.; Furtek, C.; Jones, C.J.; Lines, C.R.; Rapoport, A.M.; MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 2008, 70, 1304-12.
155. Connor, K.M.; Shapiro, R.E.; Diener, H.C.; Lucas, S.; Kost, J.; Fan, X.; Fei, K.; Assaid, C.; Lines, C.; Ho, T.W. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology, 2009, 73, 970-7.
156. Sixt, M.L.; Messlinger, K.; Fischer, M.J. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain., 2009, 132, 3134-41.
157. Iovino, M.; Feifel, U.; Yong, C.L.; Wolters, J.M.; Wallenstein, G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia, 2004, 24, 645-56.
158. Ho, T.W.; Ferrari, M.D.; Dodick, D.W.; Galet, V.; Kost, J.; Fan, X.; Leibensperger, H.; Froman, S.; Assaid, C.; Lines, C.; Koppen, H.; Winner, P.K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet, 2008, 372, 2115-23.
159. Tepper, S.J.; Cleves, C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. Investig. Drugs, 2009, 10, 711-20.
160. Li, J.; Vause, C.V.; Durham, P.L. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res., 2008, 1196, 22-32.
161. Capuano, A.; De Corato, A.; Lisi, L.; Tringali, G.; Navarra, P.; Dello Russo, C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol. Pain., 2009, 5, 43.
162. Benemei, S.; Nicoletti, P.; Capone, J.A.; Geppetti, P. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci., 2007, 28 (Suppl 2), S89-93.
163. Olesen, J.; Thomsen, L.L.; Lassen, L.H.; Olesen, I.J. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia, 1995, 15, 94-100.
164. Thomsen, L.L.; Olesen, J. Nitric oxide in primary headaches. Curr. Opin. Neurol., 2001, 14, 315-321.
165. Lazarov, N.E. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog. Neurobiol., 2002, 66, 19-59.
166. Iversen, H.K. Human migraine models. Cephalalgia, 2001, 21, 781-785.
167. Lassen, L.H.; Haderslev, P.A.; Jacobsen, V.B.; Iversen, H.K.; Sperling, B.; Olesen, J. CGRP may play a causative role in migraine. Cephalalgia, 2002, 22, 54-61.
168. Messlinger, K.; Suzuki, A.; Pawlak, M.; Zehnter, A.; Schmidt, R.F. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br. J. Pharmacol., 2000, 129, 1397-1404.
169. Strecker, T.; Dux, M.; Messlinger, K. Increase in meningeal blood flow by nitric oxide--interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia, 2002, 22, 233-241.
170. Akerman, S.; Williamson, D.J.; Kaube, H.; Goadsby, P.J. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol., 2002, 137, 62-68.
171. Olesen, J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol. Ther., 2008, 120, 157-171.
172. Kruuse, C.; Iversen, H.K.; Jansen-Olesen, I.; Edvinsson, L.; Olesen, J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia, 2010, 30(4), 467-474.
173. Vause, C.V.; Durham, P.L. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogenactivated protein kinase pathways. J. Neurochem., 2009, 110, 811-21.
174. De Alba, J.; Clayton, N.M.; Collins, S.D.; Colthup, P.; Chessell, I.; Knowles, R.G. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain, 2006, 120, 170-81.
175. Sprenger, T.; Goadsby, P.J. Migraine pathogenesis and state of pharmacological treatment options. BMC Med., 2009, 7, 71.
176. Fusayasu, E.; Kowa, H.; Takeshima, T.; Nakaso, K.; Nakashima, K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain, 2007, 128, 209-214.
177. Gallai, V.; Sarchielli, P.; Flofidi, A.; Francceschini, M.; Codini, M.; Trequattrini, A.; Palumbo, R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia, 1995, 15, 384-390.
178. Goadsby, P.J.; Edvinsson, L.; Ekman, R. Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann. Neurol., 1990, 28, 183-187.
179. Alessandri, M.; Massanti, L.; Geppetti, P.; Bellucci, G.; Cipriani, M.; Fanciullacci, M. Plasma changes of calcitonin gene-related peptide and substance P in patients with dialysis headache. Cephalalgia, 2006, 26, 1287-1293.
180. Diener, H.C. RPR100893 Study Group.RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia. 2003, 23, 183-5.
181. Goldstein, D.J.; Wang, O.; Saper, J.R.; Stoltz, R.; Silberstein, S.D.; Mathew, N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia, 1997, 17, 785-790.
182. May, A.; Goadsby, P.J. Substance P receptor antagonists in the therapy of migraine. Expert Opin. Investig. Drugs, 2001, 10, 673-678.
183. Peroutka, S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol. Interv., 2005, 5, 304-311.
184. Lazarov, N.E. Neurobiology of orofacial proprioception. Brain Res. Rev., 2007, 56, 362-383.
185. Dalsgaard, C.J.; Vincent, S.R.; Hökfelt, T.; Wiesenfeld-hallin, Z.; Gustafsson, L.; Elde, R.; Dockray, G.J. Effects of cysteamine on pain behaviour and on somatostatin and substance P-like immunoreactivity in the substantia gelatinosa of the rat. Eur. J. Pharmacol., 1984, 104, 295-301.
186. Gazelius, B.; Brodin, E.; Olgart, L.; Panopoulos, P. Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as a release inhibitor. Acta Physiol. Scand., 1981, 113, 155-159.
187. Sicuteri, F.; Geppetti, P.; Marabini, S.; Lembeck, F. Pain relief by somatostatin in attacks of cluster headache. Pain, 1984, 18, 359-365.
188. Sicuteri, F.; Renzi, D.; Geppetti, P. Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. Adv. Exp. Med. Biol., 1986, 198, 145-152.
189. Kapicioglu, S.; Gokce, E.; Kapicioglu, Z.; Ovali, E. Treatment of migraine attacks with a long-acting somatostatin analogue (Octreotide. SMS 201-995). Cephalalgia, 1997, 17, 27-30.
190. Matsubara, T.; Moskowitz, M.A.; Huang, Z. UK-14,304, R(-)- alpha-methyl-histamine and SMS201-995 block plasma protein leakage within dura mater by prejunctional mechanism. Eur. J. Pharmacol., 1992, 224, 145-150.
191. Samsam, M.; Coveñas, R.; Ahangari, M.; Yajeya, J.; Narváez, J.A.; Montes, C.; Gonzßález-Barón, S. Implication of the neuropeptides methionine enkephalin, neurotensin and somatostatin of the caudal trigeminal nucleus in the experimental migraine. Rev. Neurol., 2002, 34, 724-729.
192. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narváez, J.A. Role of neuropeptides in migraine; where do they stand in the latest expert recommendations in migraine treatment? Drug Devel. Res., 2007, 68, 298-314
193. Kemper, R.H.; Jeuring, M.; Meijler, W.J.; Korf, J.; Ter Horst, G.J. Intracisternal octreotide does not ameliorate orthodromic trigeminovascular nociception. Cephalalgia, 2000, 20, 114-121.
194. Kitazawa, T.; Terasaki, T.; Suzuki, H.; Kakee, A.; Sugiyama, Y. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J. Pharmacol. Exp. Ther., 1998, 286, 890-895.
195. Schmidt, M.; Scheidhauer, K.; Luyken, C.; Voth, E.; Hildebrandt, G.; Klug, N.; Schicha, H. Somatostatin receptor imaging in intracranial tumors. Eur. J. Nucl. Med., 1998, 25, 675-686.
196. Bartsch, T.; Levy, M.J.; Knight, Y.E.; Goadsby, P.J. Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. Pain, 2005, 117, 30-39.
197. Levy, M.J.; Matharu, M.; Goadsby, P.J. Chronic headache and pituitary tumors. Curr. Pain Headache Rep., 2008, 12, 74-8.
198. Chamberlain, M.C.; Glantz, M.J.; Fadul, C.E. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology., 2007, 69, 969-73.
199. Humphrey, P.P. The discovery of a new drug class for the acute treatment of migraine. Headache, 2007, 47(Suppl 1), S10-9.
200. Basbaum, A.I.; Jessell, T.M. In: Principles of Neural Science; Kandel, E.R., Schwartz, J.H., Jessell, T.M., Ed.; 4th ed.; McGraw Hill: New York, 2000; pp. 473-491.
201. Yaksh, T.; Young, C.; Rudy, T. systematic examination of the rat brain sites sensitive to direct application of morphin: Observation of differential effects with the periaqueductal gray. Brain Res., 1976, 114, 83-103.
202. Basbaum, A.; Field, H. The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: further studies on the anatomy of pain modulation. J. Comp. Neurol., 1979, 187, 513-532.
203. Reichling, D. B.; Kwait, G. C.; Basbaum, A. I. Anatomy and pharmachology of the periaqueductal gray contribution to antinociceptive controls. Prog. Brain Res., 1988, 77, 31-46.
204. Reichling, D.; Basbaum, A. Contribution of brainstem GABAergic circuitry to descending antinociceptive controls I. GABAimmunoreactive projection neurons in the periaqueductal gray and nucleus raphe magnus. J. Comp. Neurol., 1990, 302, 370-377.
205. Moskowitz, M.A.; Brezina, L. R.; Kuo, C. Dynorphin B-containing perivascular axons and sensory neurotransmitter mechanisms in brain blood vessels. Cephalalgia, 1986, 6, 81-86.
206. Martin-Schild, S.; Gerall, A. A.; Kastin, A. J.; Zadina, J. E. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides, 1998, 19, 1783-1789.
207. Yaksh, T. L.; Michener, S. R.; Bailey, J. E.; Harty, G. J.; Lucas, D. L.; Nelson, D. K.; Roddy, D. R.; Go, V. L. Survey of distribution of substance P, vasoactive intestinal peptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of the cat, dog, sloth and monkey. Peptides, 1988, 9, 357-372.
208. Zhang, R.X.; Mi, Z. P.; Qiao, J.T. Changes of spinal substance P, calcitonin gene-related peptide, somatostatin, Met-enkephalin and neurotensin in rats in response to formalin-induced pain. Regul. Pept., 1994, 51, 25-32.
209. Saria, A.; Hauser, K. F.; Traurig, H. H.; Turbek, C. S.; Hersh, L.; Gerard, C. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice. Neurosci. Lett., 1997, 234, 27-30.
210. Yaksh, T.L.; Elde, R. Factors governing release of methionine enkephalin-like immunoreactivity from mesencephalin and spinal cord of the cat in vivo. J. Neurophysiol., 1981, 46, 1056-1075.
211. Mosnaim, A.D.; Wolf, M.E.; Chevesich, J.; Callaghan, O.H.; Diamond, S. Plasma methionine enkephalin levels. A biological marker for migraine? Headache, 1985, 25, 259-261.
212. Mosnaim, A.D.; Chevesich, J.; Wolf, M.E.; Freitag, F.G.; Diamond, S. Plasma methionine enkephalin. Increased levels during a migraine episode. Headache, 1986, 26, 278-281.
213. Williamson, D.J.; Shepheard, S.L.; Cook, D.A.; Hargreaves, R.J.; Hill, R.G.; Cumberbatch, M.J. Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br. J. Pharmacol., 2001, 133, 807-814.
214. Bahra, A.; Walsh, M.; Menon, S.; Goadsby, P.J. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache, 2003, 43, 179-90.
215. Radat, F.; Creac'h, C.; Guegan-Massardier, E.; Mick, G.; Guy, N.; Fabre, N.; Giraud, P.; Nachit-Ouinekh, F.; Lantéri-Minet, M. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache, 2008, 48, 1026-36.
216. Katsarava, Z.; Limmroth, V.; Finke, M.; Diener, H.C.; Fritsche, G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology, 2003, 60, 1682-3.
217. Boes, C.J.; Black, D.F.; Dodick, D.W. Pathophysiology and management of transformed migraine and medication overuse headache. Semin. Neurol., 2006, 26, 232-241.
218. Biondi, D.M. Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr. Pain Headache Rep., 2003, 7, 67-75.
219. Wasay, M.; Zaki, K.S.; Khan, S.U.; Rehmani, R. Narcotic analgesics for acute migraine in the emergency room: are we meeting Headache Societies' guidelines? J. Headache Pain, 2006, 7, 413-415.
220. Howland, R.D.; Mycek, M.J. In: Pharmacology; Harvey, R.A., Champe, P.C., Ed; 3rd ed.; Lippincott Williams & Wilkins; Baltimore, 2006; pp. 520-523.
221. Bigal, M.E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W.F.; Lipton, R.B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache, 2008, 48, 1157-68.
222. Strassman, A.M.; Raymond, S.A.; Burstein, R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature., 1996, 384, 560-4.
223. Malick, A.; Burstein, R. Peripheral and central sensitization during migraine. Funct. Neurol., 2000, 15 (Suppl 3), 28-35.
224. Tajti, J.; Vécsei, L. The mechanism of peripheral and central sensitization in migraine. A literature review. Neuropsychopharmacol. Hung., 2009, 11, 15-21.
225. Levy, D.; Jakubowski, M.; Burstein, R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. USA, 2004, 101, 4274-9.
226. Burstein, R.; Jakubowski, M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol., 2004, 55, 27-36.
227. Roch, M.; Messlinger, K.; Kulchitsky, V.; Tichonovich, O.; Azev, O.; Koulchitsky, S. Ongoing activity in trigeminal wide-dynamic range neurons is driven from the periphery. Neuroscience, 2007, 150, 681-91.
228. Theoharides, T.C.; Donelan, J.; Kandere-Grzybowska, K.; Konstantinidou, A. The role of mast cells in migraine pathophysiology. Brain Res. Brain Res. Rev., 2005, 49, 65-76.
229. Zimmermann, K.; Reeh, P.W.; Averbeck, B. S+ -flurbiprofen but not 5-HT1 agonists suppress basal and stimulated CGRP and PGE2 release from isolated rat dura mater. Pain, 2003, 103, 313-20.
230. Ebersberger, A.; Takac, H.; Richter, F.; Schaible, H.G. Effect of sympathetic and parasympathetic mediators on the release of calcitonin gene-related peptide and prostaglandin E from rat dura mater, in vitro. Cephalalgia, 2006, 26, 282-9.
231. Tore, F.; Korkmaz, O.T.; Dogrukol-Ak, D.; Tunçel, N. The Effects of Vasoactive Intestinal Peptide on Dura Mater Nitric Oxide Levels and Vessel-Contraction Responses in Sympathectomized Rats. J. Mol. Neurosci., 2010, 41(2), 288-293.
232. Dublin, P.; Hanani, M. Satellite glial cells in sensory ganglia: their possible contribution to inflammatory pain. Brain Behav. Immun., 2007, 21, 592-8.
233. Ledda, M.; Blum, E.; De Palo, S.; Hanani, M. Augmentation in gap junction-mediated cell coupling in dorsal root ganglia following sciatic nerve neuritis in the mouse. Neuroscience, 2009, 164, 1538-45.
234. Dubner, R.; Ren, K. Brainstem mechanisms of persistent pain following injury. J. Orofac. Pain, 2004, 18, 299-305.
235. Burstein, R.; Collins, B.; Jakubowski, M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol., 2004, 55, 19-26.
236. Jakubowski, M.; Levy, D.; Goor-Aryeh, I.; Collins, B.; Bajwa, Z.; Burstein, R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache, 2005, 45, 850-61.
237. Jakubowski, M.; Levy, D.; Kainz, V.; Zhang, X.C.; Kosaras, B.; Burstein, R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience, 2007, 148, 573-83.
238. Goadsby, P.J.; Knight, Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5- hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br. J. Pharmacol., 1997, 122, 918-922.
239. Goadsby, P.J. Is a central action of acute antimigraine drugs essential? Cephalalgia, 1997, 17, 10-11.
240. Goadsby, P.J. Current concepts of the pathophysiology of migraine. Neurol. Clin., 1997, 15, 27-42.
241. Goadsby, P.J.; Boes, C.J. Zolmitriptan: differences from sumatriptan. Curr. Med. Res Opin., 2001, 17, S46-50.
242. Donaldson, C.; Boers, P.M.; Hoskin, K.L.; Zagami, A.S.; Lambert, G.A. The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology, 2002, 42, 374-385.
243. Lambert, G.A.; Boers, P.M.; Hoskin, K.L.; Donaldson, C.; Zagami, A.S. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res., 2002, 953, 181-188
244. Andreou, A.P.; Goadsby, P.J. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin. Investig. Drugs, 2009, 18, 789-803.
245. Barnes, N.P.; James, E.K. Migraine headache in children. Clin. Evid. (Online)., 2009, pii: 0318.
246. Farinelli, I.; De Filippis, S.; Coloprisco, G.; Missori, S.; Martelletti, P. Future drugs for migraine. Intern. Emerg. Med., 2009. 4, 367-373.
247. Holland, P.R. Modulation of trigeminovascular processing: novel insights into primary headache disorders. Cephalalgia, 2009, 29, Suppl 3:1-6.
248. Ayata, C.; Jin, H.; Kudo, C.; Dalkara, T.; Moskowitz, M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol., 2006, 59, 652-61.
249. Bigal, M.E.; Lipton, R.B. Overuse of acute migraine medications and migraine chronification. Curr. Pain Headache Rep., 2009, 13, 301-7.
250. Galletti, F.; Cupini, L.M.; Corbelli, I.; Calabresi, P.; Sarchielli, P. Pathophysiological basis of migraine prophylaxis. Prog. Neurobiol. 2009, 89, 176-92.
251. Suthisisang, C.; Poolsup, N.; Kittikulsuth, W.; Pudchakan, P.; Wiwatpanich, P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann. Pharmacother., 2007, 41, 1782-91.
252. Steiner TJ, Voelker M. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. J. Clin. Pharm. Ther., 2009, 34, 177-86.
253. Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Nonsteroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst. Rev., 2009, 8, CD006362.
254. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain., 2009, 146, 261-9.
255. Bigal, ME; Rapoport, AM; Hargreaves, R. Advances in the pharmacologic treatment of tension-type headache. Curr. Pain Headache Rep., 2008, 12, 442-446.
256. Sun-Edelstein, C; Mauskop, A. Complementary and alternative approaches to the treatment of tension-type headache. Curr. Pain Headache Rep., 2008, 12, 447-450.
257. Goadsby, P.J.; Edvinsson, L. Neuropeptide changes in a case of chronic paroxysmal hemicrania--evidence for trigeminoparasympathetic activation. Cephalalgia, 1996, 16, 448-50.
258. Vaudry, D.; Falluel-Morel, A.; Bourgault, S.; Basille, M.; Burel, D.; Wurtz, O.; Fournier, A.; Chow, B.K.; Hashimoto, H.; Galas, L.; Vaudry, H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev., 2009, 61, 283-357.
259. Rahmann, A.; Wienecke, T.; Hansen, J.M.; Fahrenkrug, J.; Olesen, J.; Ashina, M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia, 2008, 28, 226-36.
260. Hansen, J.M.; Sitarz, J.; Birk, S.; Rahmann, A.M.; Oturai, P.S.; Fahrenkrug, J.; Olesen, J.; Ashina, M. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia, 2006, 26, 992-1003.
261. Boni, L.J.; Ploug, K.B.; Olesen, J.; Jansen-Olesen, I.; Gupta, S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia, 2009, 29, 837-47.